| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-706 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0339
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y101-03013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-0006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8509 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-15 |
| filingDate |
2006-11-01^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2009-04-02^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2009513153-A |
| titleOfInvention |
Terminal oxidase and use thereof |
| abstract |
The present invention relates to a method for combating diseases affecting the system of mitochondrial oxidative phosphorylation by ectopic expression of cyanide-insensitive alternative xidase (AOX) in human cells. Successful expression of AOX in human cells and Drosophila has been shown to confer significant cyanide resistance to mitochondria, reducing oxidative stress, sensitivity to apoptosis and metabolic acidosis. AOX is well tolerated when ubiquitously expressed in an organism. AOX expression is a valuable tool for limiting adverse events of respiratory chain deficiency. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012157612-A1 |
| priorityDate |
2005-11-01^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |